News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Sunstone Life Science Ventures joins EUR 57 Million Series A Investment in Kynexis to Advance Development of Novel Therapeutics for Cognitive Disorders
Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for cognitive...
Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developing a first-in-class regenerative treatment for type 1 diabetes
Sunstone Life Science Ventures (Sunstone), a leading European venture capital firm focused on life science therapeutics, today announced that Sunstone’s Fund IV has invested in the Series A financing round of DiogenX now increased to €33.5 million ($33.8M). Press...
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of a EUR 54 million upsized financing. The financing includes investment from new investors EQT...
IO Biotech, Inc. Announces USD 75 Million Private Placement Financing
IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement for a private...
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its novel GBS vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is...
Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases
Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...